Suppr超能文献

针对人类免疫缺陷病毒1型Tat抗原的中和性人源单克隆抗体的产生与特性分析

Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.

作者信息

Moreau Emmanuel, Hoebeke Johan, Zagury Daniel, Muller Sylviane, Desgranges Claude

机构信息

INSERM EMI 0334, Hôpital St-Louis, F-75010 Paris, France.

出版信息

J Virol. 2004 Apr;78(7):3792-6. doi: 10.1128/jvi.78.7.3792-3796.2004.

Abstract

The human immunodeficiency virus Tat regulatory protein is essential for virus replication and pathogenesis. From human peripheral blood mononuclear cells of three Tat toxoid-immunized volunteers, we isolated five Tat-specific human monoclonal antibodies (HMAbs): two full-length immunoglobulin G (IgG) antibodies and three single-chain fragment-variable (scFv) antibodies. The two IgGs were mapped to distinct epitopes within the basic region of Tat, and the three scFvs were mapped to the N-terminal domain of Tat. The three scFvs were highly reactive with recombinant Tat in Western blotting or immunoprecipitation, but results were in contrast to those for the two IgGs, which are sensitive to a particular folding of the protein. In transactivation assays, scFvs were able to inhibit both active recombinant Tat and native Tat secreted by a transfected CEM cell line while IgGs neutralized only native Tat. These HMAbs were able to reduce viral p24 production in human immunodeficiency virus type 1 strain IIIB chronically infected cell lines in a dose-dependent manner.

摘要

人类免疫缺陷病毒Tat调节蛋白对于病毒复制和发病机制至关重要。我们从三名经Tat类毒素免疫的志愿者的人外周血单核细胞中分离出五种Tat特异性人单克隆抗体(HMAb):两种全长免疫球蛋白G(IgG)抗体和三种单链可变片段(scFv)抗体。这两种IgG被定位到Tat碱性区域内不同的表位,而三种scFv被定位到Tat的N端结构域。在蛋白质印迹或免疫沉淀中,这三种scFv与重组Tat反应强烈,但结果与两种IgG相反,这两种IgG对蛋白质的特定折叠敏感。在反式激活试验中,scFv能够抑制活性重组Tat和转染的CEM细胞系分泌的天然Tat,而IgG仅中和天然Tat。这些HMAb能够以剂量依赖的方式降低1型人类免疫缺陷病毒IIIB株慢性感染细胞系中的病毒p24产生。

相似文献

4
Antibody to HIV-1 Tat protein inhibits the replication of virus in culture.
Arch Virol. 1994;139(3-4):263-71. doi: 10.1007/BF01310790.
5
Tat-neutralizing antibodies in vaccinated macaques.
J Virol. 2003 Mar;77(5):3157-66. doi: 10.1128/jvi.77.5.3157-3166.2003.
8
Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 1;10(4):408-16. doi: 10.1097/00042560-199512000-00003.
9
A lipidated anti-Tat antibody enters living cells and blocks HIV-1 viral replication.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14(3):193-203. doi: 10.1097/00042560-199703010-00001.

引用本文的文献

1
New insights into pathogenesis point to HIV-1 Tat as a key vaccine target.
Arch Virol. 2021 Nov;166(11):2955-2974. doi: 10.1007/s00705-021-05158-z. Epub 2021 Aug 14.
2
Identification of a highly conserved surface on Tat variants.
J Biol Chem. 2013 Jun 28;288(26):19072-80. doi: 10.1074/jbc.M113.466011. Epub 2013 May 15.
3
Novel biopanning strategy to identify epitopes associated with vaccine protection.
J Virol. 2013 Apr;87(8):4403-16. doi: 10.1128/JVI.02888-12. Epub 2013 Feb 6.
4
A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade.
J Biol Chem. 2012 Apr 6;287(15):11942-50. doi: 10.1074/jbc.M111.319863. Epub 2012 Feb 23.

本文引用的文献

2
Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers.
J Acquir Immune Defic Syndr. 2003 May 1;33(1):47-55. doi: 10.1097/00126334-200305010-00008.
3
Tat-neutralizing antibodies in vaccinated macaques.
J Virol. 2003 Mar;77(5):3157-66. doi: 10.1128/jvi.77.5.3157-3166.2003.
4
Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants.
J Biol Chem. 2002 Sep 27;277(39):35915-9. doi: 10.1074/jbc.M204393200. Epub 2002 Jun 21.
8
Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1.
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11466-71. doi: 10.1073/pnas.97.21.11466.
10
Exploiting recombination in single bacteria to make large phage antibody libraries.
Nat Biotechnol. 2000 Jan;18(1):75-80. doi: 10.1038/71958.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验